Key Points
- Guardant Health CEO Helmy Eltoukhy sold 90,565 shares on December 15 at an average price of $103.82 for about $9.4M, reducing his stake by 4.24% to 2,047,143 shares valued at roughly $212.5M (disclosed in an SEC filing).
- The stock trades in a wide 52‑week range of $29.91–$112.43 (opened $97.47), has a market cap of $12.29B and a negative P/E, and the company recently beat quarterly EPS estimates (‑$0.39 vs. consensus ‑$0.48) with revenue up 38.5% year‑over‑year.
- Analyst and institutional sentiment is broadly positive: 23 analysts rate the stock Buy vs. 1 Sell with a consensus "Moderate Buy" target of $95.52, and institutional investors own about 92.6% of the shares.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) CTO Darya Chudova sold 5,451 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $104.04, for a total value of $567,122.04. Following the completion of the sale, the chief technology officer owned 7,012 shares of the company's stock, valued at $729,528.48. The trade was a 43.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Darya Chudova also recently made the following trade(s):
- On Monday, December 8th, Darya Chudova sold 13,664 shares of Guardant Health stock. The stock was sold at an average price of $105.04, for a total value of $1,435,266.56.
- On Monday, December 8th, Darya Chudova sold 9,271 shares of Guardant Health stock. The shares were sold at an average price of $106.00, for a total value of $982,726.00.
Guardant Health Price Performance
Shares of GH opened at $99.01 on Thursday. The business's 50-day moving average is $90.87 and its 200-day moving average is $66.79. The company has a market capitalization of $12.48 billion, a price-to-earnings ratio of -30.63 and a beta of 1.58. Guardant Health, Inc. has a fifty-two week low of $29.91 and a fifty-two week high of $112.43.
Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.09. During the same quarter in the previous year, the company earned ($0.88) EPS. The firm's revenue was up 38.5% on a year-over-year basis. Equities research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Guardant Health
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Intech Investment Management LLC raised its position in shares of Guardant Health by 37.3% in the first quarter. Intech Investment Management LLC now owns 60,187 shares of the company's stock valued at $2,564,000 after purchasing an additional 16,363 shares during the period. Edgestream Partners L.P. grew its stake in Guardant Health by 147.3% in the 2nd quarter. Edgestream Partners L.P. now owns 50,519 shares of the company's stock valued at $2,629,000 after buying an additional 30,094 shares during the last quarter. Yorktown Management & Research Co Inc acquired a new position in Guardant Health in the 2nd quarter valued at $289,000. Osterweis Capital Management Inc. bought a new position in Guardant Health in the 1st quarter worth $12,634,000. Finally, State of Wyoming acquired a new position in Guardant Health during the 2nd quarter worth $567,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several analysts recently issued reports on the company. TD Cowen increased their price objective on Guardant Health from $63.00 to $72.00 and gave the stock a "buy" rating in a report on Thursday, September 25th. Wells Fargo & Company raised their price target on Guardant Health from $93.00 to $120.00 and gave the stock an "overweight" rating in a research note on Monday. Barclays lifted their price target on Guardant Health from $85.00 to $120.00 and gave the company an "overweight" rating in a report on Monday. Stifel Nicolaus set a $73.00 price objective on Guardant Health in a report on Thursday, September 25th. Finally, Citigroup raised their price objective on shares of Guardant Health from $100.00 to $135.00 and gave the company a "buy" rating in a research report on Thursday, December 11th. Twenty-three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $95.52.
Get Our Latest Stock Report on GH
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
